Xtant Medical (XTNT) entered into a licensing agreement with Sites Medical for use of OsteoSync™ Ti porous titanium scaffold technology.
OsteoSync Ti is a highly-porous titanium scaffold. Preclinical testing has demonstrated bone attachment strength at nearly 2x that of titanium plasma spray and ~7x that of PEEK material at 5-week follow-up.
XTNT estimates that the total addressable U.S. market for its products that can use OsteoSync Ti is US $2.5BB, with a 5-year CAGR approaching 4.75%.
First products arising from this partnership will be showcased in 4Q17 at NASS. The initiative supports XTNT's intention to fill portfolio gaps via licensing agreements with strategic partners.
Sources: Xtant Medical, Inc.; sitesmedical.com; ORTHOWORLD Inc.